Influenza revaccination of elderly travelers: antibody response to single influenza vaccination and revaccination at 12 weeks.
Identifieur interne : 000A83 ( Main/Exploration ); précédent : 000A82; suivant : 000A84Influenza revaccination of elderly travelers: antibody response to single influenza vaccination and revaccination at 12 weeks.
Auteurs : J A Buxton [Canada] ; D M Skowronski ; H. Ng ; S A Marion ; Y. Li ; A. King ; J. HockinSource :
- The Journal of infectious diseases [ 0022-1899 ] ; 2001.
Descripteurs français
- KwdFr :
- Calendrier vaccinal (MeSH), Colombie-Britannique (MeSH), Facteurs temps (MeSH), Femelle (MeSH), Grippe humaine (immunologie), Grippe humaine (prévention et contrôle), Grippe humaine (virologie), Grippe humaine (étiologie), Humains (MeSH), Hémagglutinines virales (biosynthèse), Hémagglutinines virales (immunologie), Mâle (MeSH), Orthomyxoviridae (immunologie), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (immunologie), Voyage (MeSH), Études cas-témoins (MeSH).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- biosynthèse : Hémagglutinines virales.
- immunologie : Grippe humaine, Hémagglutinines virales, Orthomyxoviridae, Vaccins antigrippaux.
- prévention et contrôle : Grippe humaine.
- virologie : Grippe humaine.
- étiologie : Grippe humaine.
- Calendrier vaccinal, Colombie-Britannique, Facteurs temps, Femelle, Humains, Mâle, Sujet âgé, Sujet âgé de 80 ans ou plus, Voyage, Études cas-témoins.
English descriptors
- KwdEn :
- Aged (MeSH), Aged, 80 and over (MeSH), British Columbia (MeSH), Case-Control Studies (MeSH), Female (MeSH), Hemagglutinins, Viral (biosynthesis), Hemagglutinins, Viral (immunology), Humans (MeSH), Immunization Schedule (MeSH), Influenza Vaccines (administration & dosage), Influenza Vaccines (immunology), Influenza, Human (etiology), Influenza, Human (immunology), Influenza, Human (prevention & control), Influenza, Human (virology), Male (MeSH), Orthomyxoviridae (immunology), Time Factors (MeSH), Travel (MeSH).
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , biosynthesis : Hemagglutinins, Viral.
- chemical , immunology : Hemagglutinins, Viral, Influenza Vaccines.
- geographic : British Columbia.
- etiology : Influenza, Human.
- immunology : Influenza, Human, Orthomyxoviridae.
- prevention & control : Influenza, Human.
- virology : Influenza, Human.
- Aged, Aged, 80 and over, Case-Control Studies, Female, Humans, Immunization Schedule, Male, Time Factors, Travel.
Abstract
The antibody response to a single influenza vaccination and the effect of influenza revaccination was assessed in healthy elderly persons. Travelers > or =65 years old who had received influenza vaccine before travel were enrolled in the study and were offered a second vaccination after 12 weeks. Geographic and age-matched control subjects received a single vaccination. A second influenza vaccination was not associated with increased adverse effects. There was no significant difference between log(10) hemagglutinin-inhibiting (HI) antibody titers or an HI antibody titer > or =1:40 (considered to be protective) in 28 control subjects and 28 revaccinated travelers for any antigen. Probable protection for influenza A antigens remained high 24 weeks after a single immunization and revaccination (A/Sydney/05/97 [H3N2], 92% and 96%, and A/Beijing/262/95 [H1N1], 80% and 96%, respectively). Response to B/Harbin was less throughout the study. A/Sydney antibody titer was lower with more times vaccinated in the previous 5 years. Therefore, a second vaccine did not enhance the immune response.
DOI: 10.1086/322013
PubMed: 11424016
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influenza revaccination of elderly travelers: antibody response to single influenza vaccination and revaccination at 12 weeks.</title><author><name sortKey="Buxton, J A" sort="Buxton, J A" uniqKey="Buxton J" first="J A" last="Buxton">J A Buxton</name><affiliation wicri:level="3"><nlm:affiliation>British Columbia Centre for Disease Control, University of British Columbia, Vancouver, Canada. jane_buxton@vrhb.bc.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>British Columbia Centre for Disease Control, University of British Columbia, Vancouver</wicri:regionArea><placeName><settlement type="city">Vancouver</settlement><region type="state">Colombie-Britannique</region></placeName></affiliation></author><author><name sortKey="Skowronski, D M" sort="Skowronski, D M" uniqKey="Skowronski D" first="D M" last="Skowronski">D M Skowronski</name></author><author><name sortKey="Ng, H" sort="Ng, H" uniqKey="Ng H" first="H" last="Ng">H. Ng</name></author><author><name sortKey="Marion, S A" sort="Marion, S A" uniqKey="Marion S" first="S A" last="Marion">S A Marion</name></author><author><name sortKey="Li, Y" sort="Li, Y" uniqKey="Li Y" first="Y" last="Li">Y. Li</name></author><author><name sortKey="King, A" sort="King, A" uniqKey="King A" first="A" last="King">A. King</name></author><author><name sortKey="Hockin, J" sort="Hockin, J" uniqKey="Hockin J" first="J" last="Hockin">J. Hockin</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2001">2001</date><idno type="RBID">pubmed:11424016</idno><idno type="pmid">11424016</idno><idno type="doi">10.1086/322013</idno><idno type="wicri:Area/Main/Corpus">000A79</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000A79</idno><idno type="wicri:Area/Main/Curation">000A79</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000A79</idno><idno type="wicri:Area/Main/Exploration">000A79</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Influenza revaccination of elderly travelers: antibody response to single influenza vaccination and revaccination at 12 weeks.</title><author><name sortKey="Buxton, J A" sort="Buxton, J A" uniqKey="Buxton J" first="J A" last="Buxton">J A Buxton</name><affiliation wicri:level="3"><nlm:affiliation>British Columbia Centre for Disease Control, University of British Columbia, Vancouver, Canada. jane_buxton@vrhb.bc.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>British Columbia Centre for Disease Control, University of British Columbia, Vancouver</wicri:regionArea><placeName><settlement type="city">Vancouver</settlement><region type="state">Colombie-Britannique</region></placeName></affiliation></author><author><name sortKey="Skowronski, D M" sort="Skowronski, D M" uniqKey="Skowronski D" first="D M" last="Skowronski">D M Skowronski</name></author><author><name sortKey="Ng, H" sort="Ng, H" uniqKey="Ng H" first="H" last="Ng">H. Ng</name></author><author><name sortKey="Marion, S A" sort="Marion, S A" uniqKey="Marion S" first="S A" last="Marion">S A Marion</name></author><author><name sortKey="Li, Y" sort="Li, Y" uniqKey="Li Y" first="Y" last="Li">Y. Li</name></author><author><name sortKey="King, A" sort="King, A" uniqKey="King A" first="A" last="King">A. King</name></author><author><name sortKey="Hockin, J" sort="Hockin, J" uniqKey="Hockin J" first="J" last="Hockin">J. Hockin</name></author></analytic><series><title level="j">The Journal of infectious diseases</title><idno type="ISSN">0022-1899</idno><imprint><date when="2001" type="published">2001</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>British Columbia (MeSH)</term><term>Case-Control Studies (MeSH)</term><term>Female (MeSH)</term><term>Hemagglutinins, Viral (biosynthesis)</term><term>Hemagglutinins, Viral (immunology)</term><term>Humans (MeSH)</term><term>Immunization Schedule (MeSH)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (etiology)</term><term>Influenza, Human (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Influenza, Human (virology)</term><term>Male (MeSH)</term><term>Orthomyxoviridae (immunology)</term><term>Time Factors (MeSH)</term><term>Travel (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Calendrier vaccinal (MeSH)</term><term>Colombie-Britannique (MeSH)</term><term>Facteurs temps (MeSH)</term><term>Femelle (MeSH)</term><term>Grippe humaine (immunologie)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (virologie)</term><term>Grippe humaine (étiologie)</term><term>Humains (MeSH)</term><term>Hémagglutinines virales (biosynthèse)</term><term>Hémagglutinines virales (immunologie)</term><term>Mâle (MeSH)</term><term>Orthomyxoviridae (immunologie)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (immunologie)</term><term>Voyage (MeSH)</term><term>Études cas-témoins (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Hemagglutinins, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Hemagglutinins, Viral</term><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>British Columbia</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Hémagglutinines virales</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Grippe humaine</term><term>Hémagglutinines virales</term><term>Orthomyxoviridae</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza, Human</term><term>Orthomyxoviridae</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Case-Control Studies</term><term>Female</term><term>Humans</term><term>Immunization Schedule</term><term>Male</term><term>Time Factors</term><term>Travel</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Calendrier vaccinal</term><term>Colombie-Britannique</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Voyage</term><term>Études cas-témoins</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The antibody response to a single influenza vaccination and the effect of influenza revaccination was assessed in healthy elderly persons. Travelers > or =65 years old who had received influenza vaccine before travel were enrolled in the study and were offered a second vaccination after 12 weeks. Geographic and age-matched control subjects received a single vaccination. A second influenza vaccination was not associated with increased adverse effects. There was no significant difference between log(10) hemagglutinin-inhibiting (HI) antibody titers or an HI antibody titer > or =1:40 (considered to be protective) in 28 control subjects and 28 revaccinated travelers for any antigen. Probable protection for influenza A antigens remained high 24 weeks after a single immunization and revaccination (A/Sydney/05/97 [H3N2], 92% and 96%, and A/Beijing/262/95 [H1N1], 80% and 96%, respectively). Response to B/Harbin was less throughout the study. A/Sydney antibody titer was lower with more times vaccinated in the previous 5 years. Therefore, a second vaccine did not enhance the immune response.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11424016</PMID><DateCompleted><Year>2001</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0022-1899</ISSN><JournalIssue CitedMedium="Print"><Volume>184</Volume><Issue>2</Issue><PubDate><Year>2001</Year><Month>Jul</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of infectious diseases</Title><ISOAbbreviation>J. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Influenza revaccination of elderly travelers: antibody response to single influenza vaccination and revaccination at 12 weeks.</ArticleTitle><Pagination><MedlinePgn>188-91</MedlinePgn></Pagination><Abstract><AbstractText>The antibody response to a single influenza vaccination and the effect of influenza revaccination was assessed in healthy elderly persons. Travelers > or =65 years old who had received influenza vaccine before travel were enrolled in the study and were offered a second vaccination after 12 weeks. Geographic and age-matched control subjects received a single vaccination. A second influenza vaccination was not associated with increased adverse effects. There was no significant difference between log(10) hemagglutinin-inhibiting (HI) antibody titers or an HI antibody titer > or =1:40 (considered to be protective) in 28 control subjects and 28 revaccinated travelers for any antigen. Probable protection for influenza A antigens remained high 24 weeks after a single immunization and revaccination (A/Sydney/05/97 [H3N2], 92% and 96%, and A/Beijing/262/95 [H1N1], 80% and 96%, respectively). Response to B/Harbin was less throughout the study. A/Sydney antibody titer was lower with more times vaccinated in the previous 5 years. Therefore, a second vaccine did not enhance the immune response.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Buxton</LastName><ForeName>J A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>British Columbia Centre for Disease Control, University of British Columbia, Vancouver, Canada. jane_buxton@vrhb.bc.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skowronski</LastName><ForeName>D M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Marion</LastName><ForeName>S A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hockin</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2001</Year><Month>06</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Infect Dis</MedlineTA><NlmUniqueID>0413675</NlmUniqueID><ISSNLinking>0022-1899</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006389">Hemagglutinins, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001955" MajorTopicYN="N" Type="Geographic">British Columbia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006389" MajorTopicYN="N">Hemagglutinins, Viral</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009975" MajorTopicYN="N">Orthomyxoviridae</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014195" MajorTopicYN="Y">Travel</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2000</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2001</Year><Month>03</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>6</Month><Day>26</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>8</Month><Day>10</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>6</Month><Day>26</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11424016</ArticleId><ArticleId IdType="pii">JID001491</ArticleId><ArticleId IdType="doi">10.1086/322013</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country><region><li>Colombie-Britannique</li></region><settlement><li>Vancouver</li></settlement></list><tree><noCountry><name sortKey="Hockin, J" sort="Hockin, J" uniqKey="Hockin J" first="J" last="Hockin">J. Hockin</name><name sortKey="King, A" sort="King, A" uniqKey="King A" first="A" last="King">A. King</name><name sortKey="Li, Y" sort="Li, Y" uniqKey="Li Y" first="Y" last="Li">Y. Li</name><name sortKey="Marion, S A" sort="Marion, S A" uniqKey="Marion S" first="S A" last="Marion">S A Marion</name><name sortKey="Ng, H" sort="Ng, H" uniqKey="Ng H" first="H" last="Ng">H. Ng</name><name sortKey="Skowronski, D M" sort="Skowronski, D M" uniqKey="Skowronski D" first="D M" last="Skowronski">D M Skowronski</name></noCountry><country name="Canada"><region name="Colombie-Britannique"><name sortKey="Buxton, J A" sort="Buxton, J A" uniqKey="Buxton J" first="J A" last="Buxton">J A Buxton</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeCanadaV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A83 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A83 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeCanadaV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:11424016
|texte= Influenza revaccination of elderly travelers: antibody response to single influenza vaccination and revaccination at 12 weeks.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:11424016" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV4
| This area was generated with Dilib version V0.6.35. |  |